Drug pricing transparency has long been an area of focus for consumers and policymakers, with numerous studies highlighting the inequity in drug spending across various disease states as well as a recent substantial rise in out-of-pocket costs.
Major legislation to reduce prescription drug costs for millions of people may get sidelined now that House Democrats have begun an impeachment inquiry of President Donald Trump.
Pharmaceutical industry attacks proposals in Washington that could cut deeply into companies’ sales.
A new watchdog report says prescriptions are being rejected because doctors and insurers don’t communicate with each other.
Plans providing Medicare’s prescription drug benefit are often slow to cover the first generic competition to a branded medication, according to a new white paper by the Association for Accessible Medicines.
The public’s favorability toward the pharmaceutical industry is at its lowest point since Gallup began polling the question in 2001.
The out-of-pocket costs required to successfully manage [chronic] conditions are forcing many patients to abandon treatments or forego other necessities such as food, shelter or transportation costs. Although biosimilar medications hold great promise for decreasing health care costs, congressional action is needed to increase competition for biosimilars and unlock their cost-savings potential.
Four influential Democratic Senators delivered a message to their Republican colleagues and President Trump today: allowing Medicare to negotiate directly with Big Pharma is the best way to bring down prescription drug prices.